GRI Bio (GRI) Operating Leases (2022 - 2025)
GRI Bio (GRI) posted quarterly Operating Leases of $15000.0 for Q4 2025, down 87.39% year-over-year from $119000.0 in Q4 2024, and down 50.0% quarter-over-quarter from $30000.0 in Q3 2025.
GRI Bio (GRI) Operating Leases (2022 - 2025) Analysis & Trends
GRI Bio's Operating Leases history runs 3 years deep, the most recent figure standing at $15000.0 for Q4 2025.
- In Q4 2025, Operating Leases fell 87.39% year-over-year to $15000.0; the TTM figure through Dec 2025 stood at $15000.0 (down 87.39% YoY), while the FY2025 annual figure was $15000.0, down 87.39% from the prior year.
- Operating Leases for Q4 2025 stood at $15000.0, down from $30000.0 in the prior quarter.
- The five-year high for Operating Leases was $119000.0 in Q4 2024, with the low at $15000.0 in Q4 2025.
- The 3-year median for Operating Leases is $71000.0 (2022), against an average of $69555.6.
- Peak annual rise in Operating Leases reached 46.79% in 2025, while the deepest fall reached 87.39% in 2025.
- GRI Bio's Operating Leases stood at $71000.0 in 2022, then jumped by 67.61% to $119000.0 in 2024, then slumped by 87.39% to $15000.0 in 2025.
- Business Quant data shows GRI's Operating Leases at $15000.0 in Q4 2025, $30000.0 in Q3 2025, and $44000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | GRI Bio | 3.07 Mn | 3.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15,000.00 |
| Sep 30, 2025 | 30,000.00 |
| Jun 30, 2025 | 44,000.00 |
| Mar 31, 2025 | 58,000.00 |
| Dec 31, 2024 | 119,000.00 |
| Sep 30, 2024 | 84,000.00 |
| Jun 30, 2024 | 96,000.00 |
| Mar 31, 2024 | 109,000.00 |
| Dec 31, 2022 | 71,000.00 |